智通财经APP讯，海利生物(603718.SH)公告，公司控股子公司陕西瑞盛生物科技有限公司(简称“瑞盛生物”)于2025年8月向印度尼西亚卫生部(简称“MOH”)递交了瑞盛生物GORORISE Natural Bone Grafting Material (GORORISE天然骨移植材料)产品的注册申报资料。瑞盛生物于近日收到MOH通知，瑞盛生物的GORORISE天然骨移植材料产品获得MOH的批准。
本次获得印度尼西亚注册证的GORORISE天然骨移植材料是瑞盛生物研发和生产的一种动物源性骨修复材料，在组成成分和微观结构上均与人体天然骨组织高度相似。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.